Updated on 12 October 2012
Future studies will investigate whether T cell activation by gluten in patients with HLA-DQ2 follows similar principles.
Dr Bob Anderson, chief scientific officer at ImmusanT, commented, "Because we now know the gluten peptides responsible for celiac disease, this is a unique opportunity to interrogate the molecular events leading to a self-destructive immune response."
"ImmusanT and its collaborators continue to uncover new insights that deepen our understanding of mechanisms of immunity in celiac disease," said Leslie Williams , CEO and president of ImmusanT.
This work was supported by an Australian Research Council Linkage grant and ImmusanT.